Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect long-term safety and tolerability data of LCZ696 and
to provide open-label LCZ696 to eligible participants who completed CLCZ696G2301 study
(PARADISE-MI) if LCZ696 is shown to have a positive benefit-risk profile in comparison to
ramipril in reducing risk of cardiovascular (CV) mortality and development of heart failure
in participants enrolled in the PARADISE-MI study.